• Tomoko Watanabe, Toshinori Ito, Gen Inoue, Seiji Ohtori, Keiko Kitajo, Hideo Doya, Kazuhisa Takahashi, and Toshihide Yamashita.
• Department of Neurobiology, Graduate School of Medicine, Chiba University, Chiba, Japan.
• J. Neurosci. Res. 2008 Dec 1;86(16):3566-74.

AbstractInflammatory pain, characterized by a decrease in the nociceptive threshold, arises through the actions of inflammatory mediators, and one of the key molecules is nerve growth factor (NGF). Here we report that the administration of neutralizing antibody to the neurotrophin receptor p75 (p75(NTR)) blocks hyperalgesia, which develops with complete Freund's adjuvant (CFA)-induced inflammation or with an intraplantar injection of NGF. Although CFA injection results in the up-regulation of calcitonin gene-related peptide (CGRP) levels in the primary sensory neurons, blocking p75(NTR) abolishes this effect. We further demonstrate that pro-NGF is the predominant ligand of p75(NTR) in vivo. Plasmin treatment, which is intended to decompose pro-NGF, ameliorates CFA-induced hyperalgesia. In addition, an intraplantar injection of pro-NGF induces hyperalgesia. These data together suggest that pro-NGF, as well as mature NGF, binding to p75(NTR) plays an important role in inflammation-induced hyperalgesia. Interference in the binding may provide a therapeutic approach for the treatment of inflammatory pain.(c) 2008 Wiley-Liss, Inc.

52 keywords...

hide…